VELCADE,Rituximab,Cyclophosphamide and Decadron
Overall response rate and Time to disease progression using this regimen in patients with low-grade B-Cell Non-Hodgkin's Lymphoma.
Lymphoma, Non-Hodgkin|Lymphoma, B-Cell
DRUG: VELCADEÂ®|DRUG: Rituximab|DRUG: Cyclophosphamide|DRUG: Decadron
Overall Response Rate Using This Regimen in Patients With Low-grade B-Cell Non-Hodgkin's Lymphoma., Percentage of complete responders plus percentage of partial responders equals overall response rate., 4 years
Overall Survival, The study was closed prematurely due to slow accrual. When the study closed only two patients had died, making the OS 83%., 4 years
This is a phase II open label study that is looking at the VRCD combination regimen in patients with previously untreated low-grade Non-Hodgkin's Lymphoma. Treatment will start by combining oral dexamethasone and cyclophosphamide with intravenous VELCADE, rituximab. Chemotherapy cycles will be given as outlined below every 35-days and will continue until two cycles beyond complete remission (CR), toxicity, patient's withdrawal, disease progression, or a maximum of 8 cycles.